Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug-resistant TB news

Show

From To
South Africa: Bedaquiline approved to treat multi-drug resistant tuberculosis

The Medicines Control Council has approved Janssen Pharmaceutica's bedaquiline, the first drug specifically designed for treating multi-drug resistant tuberculosis (MDR-TB) to reach the market. Janssen is a subsidiary of Johnson & Johnson.

Published
12 hours ago
From
Business Day
Minsk has extremely high levels of drug-resistant TB, a study in Belarus reveals

Multidrug-resistant (MDR)-TB was found in 35.3% (95% CI 27.7–42.8) of new patients and 76.5% (95% CI 66.1–86.8) of those previously treated. Overall, nearly one in two patients enrolled had MDR-TB. Extensively drug-resistant TB was reported in 15 of the 107 MDR-TB patients (14.0%, 95% CI 7.3–20.7). The findings of this survey in Minsk city are alarming and represent the highest proportions of MDR-TB ever recorded in the world.

Published
29 September 2014
From
TB Europe Coalition
What does new drug PaMZ mean for TB and HIV treatment?

The development of PaMZ has been hailed as a breakthrough. But what do the experts think?

Published
02 September 2014
From
The Guardian
Acquired rifampicin resistance more likely in HIV-coinfected patients

Patients with HIV and tuberculosis were more likely to develop acquired rifampicin resistance when treated with a thrice-weekly tuberculosis treatment compared with patients not coinfected with HIV, according to researchers from the National Institute for Research in Tuberculosis in India. The rate of bacteriologic failure was 4% among patients without HIV. Among patients with HIV, the rates were 9% for those not receiving ART and 5% for those receiving ART.

Published
02 September 2014
From
Healio
Apathy in TB fight: The Economist Intelligence Unit

A new report on tuberculosis calls for raising the profile of TB, fight apathy and lack of compelling ambition in addressing the disease.

Published
04 July 2014
From
Stop TB Partnership
South Africa: Litigation threat may prompt access to cheaper DR-TB drug

South Africa may finally allow access to a cheaper form of the drug-resistant tuberculosis (DR-TB) drug linezolid following the lodging of a high court case.

Published
16 June 2014
From
Health-e
South Africa: Government to introduce new drug-resistant TB drugs

Government’s small-scale introduction of the first new TB drug in four decades is saving lines and paving the way for more, better and cheaper drugs to treat drug-resistant TB. Many wonder if they will come fast enough for those who need them.

Published
16 June 2014
From
Health-e
South African activists: DR-TB a ‘public health emergency’

Civil society groups have called for government to declare drug-resistant tuberculosis (DR-TB) a public health emergency, as the DR-TB response remains underfunded.

Published
16 June 2014
From
Health-e
TB drug approvals, distribution deal inches options forward, but MDR TB treatment access still uncertain where needed most

Last week’s important developments in TB treatment included the announcement that bedaquiline, the currently most promising medicine for multi-drug-resistant tuberculosis, will become available to patients in 130 low- and middle-income countries through the Stop TB Partnership’s Global Drug Facility.

Published
14 May 2014
From
Science Speaks
UNITAID approves grants of $160 million, for hepatitis C, MDR-TB and malaria drugs

Breakthrough new medicines for hepatitis C and drug-resistant TB and largest-yet global programme for seasonal malaria chemoprevention to be made available for low- and middle-income countries as part of $160 million of new grants funded by UNITAID

Published
07 May 2014
From
UNITAID
← First12345...14Next →

Filter by country